Medtronic Invests $90M in Anteris to Advance TAVR Technology

Event summary

  • Anteris Technologies Global Corp. raised $320M in total capital, including a $90M strategic investment from Medtronic.
  • The funding will support the global PARADIGM trial for the DurAVR® Transcatheter Heart Valve (THV).
  • The PARADIGM trial, a head-to-head study, will enroll approximately 1000 patients to compare DurAVR® THV with commercially available TAVRs.
  • Anteris' DurAVR® THV is designed to mimic the performance of a healthy human aortic valve using ADAPT® tissue technology.
  • The investment follows Anteris’ underwritten offering of common stock, positioning the company for global commercialization.

The big picture

Anteris' $320M capital raise, backed by Medtronic, underscores the strategic importance of advancing TAVR technology. The investment highlights the competitive dynamics in the structural heart market, where innovation in valve design and clinical evidence are critical for market share. Medtronic's involvement suggests a validation of Anteris' technology and a potential shift in the TAVR landscape, as the industry focuses on improving long-term patient outcomes.

What we're watching

Clinical Trial Progress
The pace at which the PARADIGM trial enrolls patients and delivers interim data will signal DurAVR® THV's competitive positioning.
Regulatory Approval
Whether Anteris can secure regulatory approval for DurAVR® THV will determine its market entry strategy and commercialization timeline.
Strategic Collaboration
How Medtronic's investment evolves into broader collaboration could impact Anteris' long-term growth and market reach.